Genes
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
85,013 comparisons from ClinicalTrials.gov. Counted 2026-11-10.
Most participants first33,758 with no events in either group come last681 to 700 of 85,013
| Comparison | With the outcome | Risk difference, 95% interval | Participants | Trial |
|---|---|---|---|---|
| Ticagrelor 90 mg vs ASA 100 mg: Number of Participants With All-Cause Death | 68 of 6,589 58 of 6,610 | 0.2 points -0.2 to 0.5 | 13,199 | NCT01994720 [SOCRATES -Acute Stroke Or Transient IsChaemic Attack TReated With Aspirin or Ticagrelor and Patient OutcomES] |
| Ticagrelor 90 mg vs ASA 100 mg: Number of Participants With Fatal Stroke | 18 of 6,589 17 of 6,610 | 0.0 points -0.2 to 0.2 | 13,199 | NCT01994720 [SOCRATES -Acute Stroke Or Transient IsChaemic Attack TReated With Aspirin or Ticagrelor and Patient OutcomES] |
| Ticagrelor 90 mg vs ASA 100 mg: Number of Participants With Composite of Ischaemic Stroke, MI and CV Death | 423 of 6,589 475 of 6,610 | -0.8 points -1.6 to 0.1 | 13,199 | NCT01994720 [SOCRATES -Acute Stroke Or Transient IsChaemic Attack TReated With Aspirin or Ticagrelor and Patient OutcomES] |
| Ticagrelor 90 mg vs ASA 100 mg: Number of Participants by Severity of Stroke and Overall Disability | 1,107 of 6,589 1,194 of 6,610 | -1.3 points -2.6 to 0.0 | 13,199 | NCT01994720 [SOCRATES -Acute Stroke Or Transient IsChaemic Attack TReated With Aspirin or Ticagrelor and Patient OutcomES] |
| Ticagrelor 90 mg vs ASA 100 mg: Number of Participants With Stroke | 390 of 6,589 450 of 6,610 | -0.9 points -1.7 to -0.1 | 13,199 | NCT01994720 [SOCRATES -Acute Stroke Or Transient IsChaemic Attack TReated With Aspirin or Ticagrelor and Patient OutcomES] |
| Ticagrelor 90 mg vs ASA 100 mg: Net Clinical Outcome | 457 of 6,589 508 of 6,610 | -0.7 points -1.6 to 0.1 | 13,199 | NCT01994720 [SOCRATES -Acute Stroke Or Transient IsChaemic Attack TReated With Aspirin or Ticagrelor and Patient OutcomES] |
| Ticagrelor 90 mg vs ASA 100 mg: Number of Participants With Disabling Stroke | 277 of 6,589 307 of 6,610 | -0.4 points -1.1 to 0.3 | 13,199 | NCT01994720 [SOCRATES -Acute Stroke Or Transient IsChaemic Attack TReated With Aspirin or Ticagrelor and Patient OutcomES] |
| Ticagrelor 90 mg vs ASA 100 mg: Number of Participants With MI | 25 of 6,589 21 of 6,610 | 0.1 points -0.1 to 0.3 | 13,199 | NCT01994720 [SOCRATES -Acute Stroke Or Transient IsChaemic Attack TReated With Aspirin or Ticagrelor and Patient OutcomES] |
| Double Blind Phase: Ad26.COV2.S vs Double Blind Phase: Placebo: Double Blind Phase: Number of Participants With First Occurrence of Molecularly Confirmed Moderate to Severe/Critical COVID-19 Regardless of Serostatus With Onset at Least 14 Days After the Second Vaccination | 14 of 6,813 53 of 6,370 | -0.6 points -0.9 to -0.4 | 13,183 | NCT04614948 A Study of Ad26.COV2.S for the Prevention of SARS-CoV-2-mediated COVID-19 in Adults |
| Ticagrelor 90 mg vs ASA 100 mg: Number of Participants With Premature Discontinuation of Study Drug Due to Any Bleeding Adverse Event | 82 of 6,549 37 of 6,581 | 0.7 points 0.4 to 1.0 | 13,130 | NCT01994720 [SOCRATES -Acute Stroke Or Transient IsChaemic Attack TReated With Aspirin or Ticagrelor and Patient OutcomES] |
| Ticagrelor 90 mg vs ASA 100 mg: Number of Participants With PLATO Major Bleeding Event | 31 of 6,549 38 of 6,581 | -0.1 points -0.4 to 0.1 | 13,130 | NCT01994720 [SOCRATES -Acute Stroke Or Transient IsChaemic Attack TReated With Aspirin or Ticagrelor and Patient OutcomES] |
| ASA 100mg vs Ticagrelor 90mg: serious adverse events | 533 of 6,581 532 of 6,549 | -0.0 points -1.0 to 0.9 | 13,130 | NCT01994720 [SOCRATES -Acute Stroke Or Transient IsChaemic Attack TReated With Aspirin or Ticagrelor and Patient OutcomES] |
| Epanova vs Placebo: deaths from any cause | 373 of 6,539 333 of 6,539 | 0.6 points -0.2 to 1.4 | 13,078 | NCT02104817 Outcomes Study to Assess STatin Residual Risk Reduction With EpaNova in HiGh CV Risk PatienTs With Hypertriglyceridemia |
| Epanova vs Placebo: serious adverse events | 2,259 of 6,532 2,195 of 6,535 | 1.0 points -0.6 to 2.6 | 13,067 | NCT02104817 Outcomes Study to Assess STatin Residual Risk Reduction With EpaNova in HiGh CV Risk PatienTs With Hypertriglyceridemia |
| Darapladib 160 mg vs Placebo: Number of Participants With First Occurrence of Any Component of the Composite of Major Adverse Cardiovascular Events (Cardiovascular [CV] Death, Non-fatal MI or Non-fatal Stroke) During the Time Period for Follow-up of CV Events | 824 of 6,504 838 of 6,522 | -0.2 points -1.3 to 1.0 | 13,026 | NCT01000727 The Stabilization Of pLaques usIng Darapladib-Thrombolysis In Myocardial Infarction 52 Trial |
| Darapladib 160 mg vs Placebo: Number of Participants With Urgent Coronary Revascularization for Myocardial Ischemia During the Time Period for Follow-up of Cardiovascular Events | 237 of 6,504 218 of 6,522 | 0.3 points -0.3 to 0.9 | 13,026 | NCT01000727 The Stabilization Of pLaques usIng Darapladib-Thrombolysis In Myocardial Infarction 52 Trial |
| Darapladib 160 mg vs Placebo: Number of Participants With First Occurrence of Any Component of the Composite of All-cause Mortality, Non-fatal MI, or Nonfatal Stroke During the Time Period for Follow-up of Cardiovascular Events | 914 of 6,504 928 of 6,522 | -0.2 points -1.4 to 1.0 | 13,026 | NCT01000727 The Stabilization Of pLaques usIng Darapladib-Thrombolysis In Myocardial Infarction 52 Trial |
| Darapladib 160 mg vs Placebo: Number of Participants With First Occurrence of Any Event in the Composite of Total Coronary Events (CHD Death, Non-fatal MI, Hospitalization for Unstable Angina, or Any Coronary Revascularization Procedure) During the Time Period for FU of CV Events | 1,290 of 6,504 1,352 of 6,522 | -0.9 points -2.3 to 0.5 | 13,026 | NCT01000727 The Stabilization Of pLaques usIng Darapladib-Thrombolysis In Myocardial Infarction 52 Trial |
| Darapladib 160 mg vs Placebo: Number of Participants With First Occurrence of MI (Fatal/Nonfatal) During the Time Period for Follow-up of Cardiovascular Events | 547 of 6,504 564 of 6,522 | -0.2 points -1.2 to 0.7 | 13,026 | NCT01000727 The Stabilization Of pLaques usIng Darapladib-Thrombolysis In Myocardial Infarction 52 Trial |
| Darapladib 160 mg vs Placebo: Number of Participants With CHD Death During the Time Period for Follow-up of Cardiovascular Events | 211 of 6,504 241 of 6,522 | -0.5 points -1.1 to 0.2 | 13,026 | NCT01000727 The Stabilization Of pLaques usIng Darapladib-Thrombolysis In Myocardial Infarction 52 Trial |
Response
The first 2 of this page's 20 results. GET /api/comparisons/v1?page=35
{
"data": {
"total": 85013,
"results": [
{
"id": "NCT01994720-9efcc190",
"title": "Ticagrelor 90 mg vs ASA 100 mg: Number of Participants With All-Cause Death",
"summary": "68 of 6589 against 58 of 6610; risk difference 0.2 points, 95% interval -0.2 to 0.5; NCT01994720, [SOCRATES -Acute Stroke Or Transient IsChaemic Attack TReated With Aspirin or Ticagrelor and Patient OutcomES]",
"record": "/library/comparisons/NCT01994720-9efcc190",
"nct_id": "NCT01994720",
"kind": "outcome",
"participants": 13199,
"risk_difference": {
"value": 0.0015456467238181074,
"lower": -0.0018039603592624421,
"upper": 0.004927563031373301
},
"group_1": "68 of 6,589",
"group_2": "58 of 6,610",
"difference": "0.2 points",
"interval": "-0.2 to 0.5",
"trial_title": "[SOCRATES -Acute Stroke Or Transient IsChaemic Attack TReated With Aspirin or Ticagrelor and Patient OutcomES]"
},
{
"id": "NCT01994720-ad276aef",
"title": "Ticagrelor 90 mg vs ASA 100 mg: Number of Participants With Fatal Stroke",
"summary": "18 of 6589 against 17 of 6610; risk difference 0.0 points, 95% interval -0.2 to 0.2; NCT01994720, [SOCRATES -Acute Stroke Or Transient IsChaemic Attack TReated With Aspirin or Ticagrelor and Patient OutcomES]",
"record": "/library/comparisons/NCT01994720-ad276aef",
"nct_id": "NCT01994720",
"kind": "outcome",
"participants": 13199,
"risk_difference": {
"value": 0.0001599649532790749,
"lower": -0.0016806463634924205,
"upper": 0.0020137615073471922
},
"group_1": "18 of 6,589",
"group_2": "17 of 6,610",
"difference": "0.0 points",
"interval": "-0.2 to 0.2",
"trial_title": "[SOCRATES -Acute Stroke Or Transient IsChaemic Attack TReated With Aspirin or Ticagrelor and Patient OutcomES]"
}
],
"no_events": 33758,
"columns": [
{
"key": "title",
"label": "Comparison"
},
{
"key": "group_1",
"label": "With the outcome",
"under": "group_2"
},
{
"key": "difference",
"label": "Risk difference, 95% interval",
"under": "interval"
},
{
"key": "participants",
"label": "Participants"
},
{
"key": "nct_id",
"label": "Trial",
"under": "trial_title"
}
],
"order": "Most participants first",
"kinds": {
"all": 85013,
"outcome": 33568,
"serious-adverse-events": 31897,
"deaths": 19548
}
},
"release": "trial-comparisons-2026-03-23-0.1.0",
"terms": [
{
"source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
"license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "Freely available. Acknowledgement requested"
},
{
"source": "ClinicalTrials.gov",
"license": "none stated",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "None stated"
}
],
"next": "/api/comparisons/v1?page=36",
"request_id": "0_dntqKUT5PHGp9r"
}ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
ClinicalTrials.gov
Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.
Patent publications
Paste a sequence and see the patents that disclose it.
For invited accounts.
Opens sequences.conductscience.org
For software
Every answer on this page is also JSON, under /api/comparisons/v1. No key.
GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome
Ask an assistant